Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Involved! Home
Patient Information

Peer Reviewed and Published Articles

The following are published articles authored by Type-1 Diabetes TrialNet investigators and researchers.

TrialNet Study Group Publications

  1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop.  Diabetes 2004; 53:250-264.

  2. Lachin JM.  The role of measurement reliability in clinical trials.  Clinical Trials 2004; 1:553-566.

  3. Lachin JM. Maximum Information Designs.  Clinical Trials 2005; 2:453-464.

  4. Lachin JM. A review of methods for futility stopping based on conditional power.  Statistics in Medicine 2005; 24:2747-2764.

  5. Lachin JM. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.  Statistics in Medicine 2006; 25:3348-3365.

  6. Lachin JM, Younes N.  A composite design for transition from a preliminary to a full-scale study.  Statistics in Medicine 2007; 26:5014–5032.

  7. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and the Type 1 Diabetes TrialNet Study Group.  Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network.  Annals of the New York Academy of Sciences 2008; In Press.

  8. Skyler JS and the Type 1 Diabetes TrialNet Study Group.  Update on Worldwide Efforts to Prevent Type 1 Diabetes.  Annals of the New York Academy of Sciences 2008; In Press.

  9. Greenbaum CJ, Mandrup-Poulsen T,  Friedenberg-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group.  Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes.   Diabetes Care 2008; 31: 1966-1971.

  10. Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.  Pediatric Diabetes 2008: [Epub ahead of print] doi: 10.1111/j.1399-5448.2008.00464.

  11. Chase HP, Lescheck E, Rafkin-Mervis L, Krause-Steinrauf H, Chritton S, Asare S, Adams S, Skyler JS, Clare-Salzier M, and the Type 1 Diabetes Trialnet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes: A Pilot Trial. iCAN: Infant, Child and Adolescent Nutrition 2009: 99-107.

  12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz D, Wherrett D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study Group.  Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function.  New England Journal of Medicine 2009; 361:2143-2152.

  13. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, and the TrialNet MMF/DZB Study Group.  Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes.  Diabetes Care 2009; In Press.

  14. Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb PA, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM,  and The Type 1 Diabetes TrialNet Research Group.  Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays in Subjects with Early Type 1 Diabetes.  Diabetes 2009; 58:2588-2595.

back to top of page

DPT-1 Study Group Publications

  1. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1).  Implementation of Screening and Staging of Relatives. Transplantation Proceedings 1995; 27: 3377.

  2. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The Diabetes Prevention Trial–Type 1 Study Group.  Islet Cell Antibody-Positive Relatives With Human Leukocyte Antigen DQA1*0102, DQB1*0602: Identification by the Diabetes Prevention Trial-Type 1.  Journal of Clinical Endocrinology & Metabolism 2000; 85:1255-1260

  3. Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1 Diabetes Study Group.  Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria.  Diabetes 2001; 50:470-476

  4. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial–Type 1 Study Group.  First-phase Insulin Release During The Intravenous Glucose Tolerance Test As A Risk Factor For Type 1 Diabetes.  Journal of Pediatrics 2001; 138:244-249

  5. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators.  Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1.  Diabetes 2001; 50: 1735-1740.

  6. Diabetes Prevention Trial - Type 1 Diabetes Study Group.  Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus.  New England Journal of Medicine 2002; 346:1685-1691.

  7. Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators.  Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by Relationship to Proband.  Annals of the New York Academy of Sciences 2002; 958:254-258.

  8. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial–Type 1 Study Group.  Screening Strategies for the Identification of Multiple Antibody Positive Relatives of Individuals with Type 1 Diabetes.  Journal of Clinical Endocrinology & Metabolism 2003; 88:103-108.

  9. Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on behalf of the DPT-1 Study Group.  Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes.  Journal of Autoimmunity 2004; 23:275-279.

  10. Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group.   Male sex increases the risk of autoimmunity but not type 1 diabetes.  Diabetes Care 2004; 27:1985-1990.

  11. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J, DPT-1 Study Group.   High Frequency of Abnormal Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes Prevention Trial – Type 1 Diabetes. Diabetologia 2005; 48:68-74.

  12. Diabetes Prevention Trial - Type 1 Diabetes Study Group.  Effects of Oral Insulin in Relatives of Patients with Type 1 Diabetes Mellitus.  Diabetes Care 2005; 28:1068-1076.

  13.  Rhodes, ET, Wolfsdorf, JI, Cuthbertson, DD, Feldman, HA, Ludwig, DS; Diabetes Prevention Trial-Type 1 Study Group.  Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes.  Diabetes Care 2005; 28:1948-1953.

  14. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group.  Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1.  Diabetes Care 2006; 29:  643-649.

  15. Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group.  The Rise and Fall of Insulin Secretion in Type 1 Diabetes Mellitus.  Diabetologia 2006; 49: 261-270.

  16. Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer JP, Cuthbertson D, Chase HP, Eisenbarth GS, and the DPT-1 Study Group.  Pre-Type 1 Diabetes Dysmetabolism:  Maximal sensitivity achieved with both Oral and Intravenous Glucose Tolerance Testing.  Journal of Pediatrics 2007; 150:31-36.

  17. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D, and the DPT-1 Study Group.  Specific HLA DQ Influence on Expression of Anti-Islet Autoantibodies and Progression to Type 1 Diabetes.  Journal of Clinical Endocrinology & Metabolism 2006; 91: 1705-1713.

  18. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group.  Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial- Type 1.  Diabetes Care 2007; 30:38-42.

  19. Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group.  Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.  Diabetologia 2007; 50:1603-1606.

  20. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-Type 1 Study Group.  The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes.  Diabetes Care 2007; 30:2314–2320.
     
  21. Johnson, SB, Baughcum, AE,  Hood K, Rafkin-Mervis, LE,  Schatz, DA, for the DPT-1 Study Group.  Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes.  Diabetes Care, 2007; 30:2193–2198.

  22. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, and the Diabetes Prevention Trial-1 Study Group.  A Risk Score for Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention Trial-Type 1.  Diabetes Care 2008; 31: 528-533.

  23. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group.    Glucose and C-peptide Changes in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1.   Diabetes Care 2008; 31: Jul 23. [Epub ahead of print].

  24. Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study Group.  Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial.  Diabetes 2008; 57: 2348-2359.

  25. Sherr J, Sosenko J, Skyler JS, Herold K.  Prevention of Type 1 diabetes. The time has come.  Nature Clinical Practice Endocrinology & Metabolism 2008; 4:334-343.

  26. Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. Pediatric Diabetes 2008; [Epub ahead of print]  doi: 10.1111/j.1399-5448.2008.00463.x.

  27. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group.   Incident Dysglycemia and the Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1.  Submitted for Publication.

  28. Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group.  Subjects diagnosed with diabetes through the Diabetes Prevention Trial Type 1 are often asymptomatic and have normal hemoglobin A1c levels at onset.  Submitted for Publication.

  29. Orban T, Sosenko JM, Cuthbertson D,  Krischer JP,  Skyler JS, Jackson R,  Yu L, Palmer JP, Schatz DA, Eisenbarth GS, and the DPT-1 Study Group. Pancreatic Islet Cell Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes Care 2009; 32:2269-2274.

  30. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler, JS, for the DPT-1 Study Group.  Progression to diabetes in relatives of patients with type 1 diabetes:  mechanisms and mode of onset.  Diabetes; In Press.

  31. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum CJ, Eisenbarth GS, Skyler JS, and the DPT-1 Study Group.   Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants.  Diabetes Care; In Press.

back to top of page

Abstracts Published

  1. DPT-1 Study Group.  The Diabetes Prevention Trial of Type I Diabetes (DPT-1).  Diabetes 1994; 43(Suppl 1):159A

  2. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Implementation of Screening and Staging of Relatives.  Diabetes 1995; 44(Suppl 1):129A.

  3. Schatz D for the DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Design and Implementation of the Oral Antigen (Insulin) Protocol.  Diabetes 1995; 44(Suppl 1):230A.

  4. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Progress Report.  Autoimmunity 1995; 21:66.

  5. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J, for the DPT-1 Study Group.  Differential Expression of Autoantibodies by DQA1*0102,DQB1*0602+ Relatives of The Diabetes Prevention Trial-1 (DPT-1).  Autoimmunity 1996; 24(Suppl 1):52.

  6. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Enrollment Report. Diabetes 1997; 46(Suppl 1):163A.
       
  7. DPT-1 Study Group.  Demographics of Relatives Screened and ICA Positive in The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1).  Diabetes 1997; 46(Suppl 1):142A.  
     
  8. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Progress Report.  Diabetologia 1997; 40(Suppl 1):A66. 
      
  9. DPT-1 Study Group.  The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):  Demographics of Relatives Screened and ICA Positive. Diabetologia 1997; 40(Suppl 1):A78.   

  10. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J,  for the DPT-1 Study Group.  Role of DQA1*0102/DQB1*0602 In Risk Characterization: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetologia 1997; 40(Suppl 1):A48.   

  11. Eastman RC, Cowie CC, Harmon J, and the DPT-1 Study Group.  Potential Cost-Effectiveness of Primary Prevention of Insulin-Dependent Diabetes Mellitus. Diabetologia 1997; 40(Suppl 1):A39.   

  12. Cowie C, Cuthbertson D, Krischer J, Wilson D, Maclaren N, and the DPT-1 Study Group.  Demographic Characteristics of Islet Cell Antibody Positivity (ICA+) in The Diabetes Prevention Trial for Type 1 Diabetes (DPT-1).  Diabetes 1998; 47(Suppl 1):A146.

  13. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J, and the DPT-1 Study Group Characteristics of HLA DQA1*0102 DQB1*0602 Relatives Identified in The Diabetes Prevention Trial - Type 1 Diabetes (DPT-1).  Diabetes 1998; 47(Suppl 1):A236.

  14. Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group.  Undiagnosed Hyperglycemia in Relatives of Type 1 Diabetes Patients.  Diabetes 1998; 47(Suppl 1):A236.

  15. Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group.  Silent Type 1 Diabetes.  Diabetes 1999; 48:(Suppl 1):A81.

  16. Palmer J, Wei, Greenbaum C, Krischer J, Cuthbertson D, and the DPT-1 Study Group.  The DPT-1 Intravenous Insulin Suppresses Endogenous Insulin Secretion But Causes Post-Prandial Glucose Intolerance.  Diabetes 1999; 48:(Suppl 1):A295.

  17. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Eisenbarth GS, Krischer JP, and the DPT-1 Study Group.  Expression of GAD65 or ICA 512 (IA-2) Autoantibodies Amongst Cytoplasmic ICA Positive Relatives is Associated with Eligibility for DPT-1.  Diabetes 1999; 48:(Suppl 1):A214.

  18. Chase P, Cuthbertson D, Dolan L, Kaufman F, Krischer J, Schatz D, White N, Wilson D, Wolfsdorf J, and the DPT-1 Study Group.  First Phase Insulin Release (FPIR) During the Initial Intravenous Glucose Tolerance Test (IV-GTT) in the Diabetes Prevention Trial (DPT-1).  Diabetes 1999; 48:(Suppl 1):A238-239.

  19. Kaufman F, Cuthbertson D, Krischer J and the DPT-1 Study Group.  HbA1c Corrlatated with Fasting and Postprandial Glucose Levels in Subjects in the Diabetes Prevention Trial-type 1 (DPT-1).  Diabetes 2001; 50(Suppl 1) A96

  20. Kaufman F, Rafkin-Mervis L, Ricker A, Wherrett D and the DPT-1 Study Group. Recruitment of Subjects into the Diabetes Prevention Trial-Type 1 (DPT-1):Strategies and Progress Report from 1994-2000.  Diabetes 2001; 50(Suppl 1) A96

  21. Navidi G, Kolva R, Younes N, Zhou A.  Use of Barcodes for Specimen Tracking to Maintain Patient Confidentiality and Quality Control Measures.  Controlled Clinical Trials 2003; 24(3S): 218S.

  22. Zhou A, Younes N, Pierre D, Krause-Steinrauf H. TrialNet Document and Sample Tracking System.  Controlled Clinical Trials 2003; 24(3S): 219S.

  23. Paula Friedenberg P, Lachin J, for the TrialNet Study Group.  Sample Size Evaluaton for Studies of Beta-Cell Function Using the Log(C-Peptide + 1) Transformation.  Clinical Trials2004; 2: 256.

  24. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson  D, Eisenbarth GS, Krischer J, Schatz D.  Diabetes Prevention Trial (DPT)-1: Influence of Protective HLA-DQ Alleles and Genotypes on Expression of Autoantibodies (Aab) and Progression to Type 1 Diabetes (T1DM).  Diabetes 2004; 53(Suppl 1):A29(125-OR)

  25. Sosenko JM, Greenbaum CJ, Palmer JP, Cowie CC, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1 Study Group.  Fasting Insulin Secretion Is Maintained More Than Stimulated Insulin Secretion with Progression to Type 1 Diabetes (T1D) in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2004; 53(Suppl 1):A425 (1783-P)

  26. Rhodes E, Wolfsdorf J, Feldman H, Ludwig D, DPT-1 Study Group.  Effect of Low-Dose Insulin Treatment on Body Weight and Adiposity in Children at Risk of Type 1 Diabetes Mellitus.  Diabetes 2004; 53(Suppl 1):A415 (1743-P)

  27. Sosenko JM, Palmer JP, Greenbaum CJ, Cowie CC, Mahon J, Chase HP, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1 Study Group.  The 2-hr-Glucose and the AUC Glucose-AUC C-Peptide Ratio as Predictors of T1D in Diabetes Prevention Trial-Type 1 (DPT-1) Participants.  Diabetes 2005; 54(Supplement 1): A456 (1897-P).

  28. Quinlan S, Krause-Steinrauf H, Gottlieb P, for the TrialNet Study Group.  Recruitment and Informed Consent for a Clinical Trial in Subjects with New-Onset Diabetes Mellitus. Clinical Trials 2005; 2: S57.

  29. Lachin JM, Friedenberg P, Greenbaum C, Colman P, on behalf of Type 1 Diabetes TrialNet.  The Mixed Meal Tolerance Test Versus the IV Glucagon Stimulation Test for the Assessment of Beta Cell Function in Type 1 Diabetes.  Proceedings of the Australian Diabetes Society 2006; Abstract 301, p.125

  30. Barker JM, Babu S, Fernando M,  Greenbaum C, Mahon J, Skyler JS, Eisenbarth GS, and the TrialNet study group.  Low prevalence of DQA*0102 DQB*0602 subjects with Trialnet Initial Biochemical Autoantibody Screening.  Diabetes 2006; 55:(Supplement):  A251 (1061-P).

  31. Lachin JM, Friedenberg P, Greenbaum C, and Type 1 Diabetes TrialNet.  The Mixed Meal Tolerance Test versus the IV Glucagon Stimulation Test for the Assessment of Beta Cell Function in Type 1 Diabetes.  Diabetes 2006; 55:(Supplement):  A537 (2325-PO).

  32. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson DD, Lachin J, Skyler JS, and the DPT-1 Study Group.   A Risk Score for Type 1 Diabetes Derived from Participants in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2007; 56:(Supplement 1): A-55 (Abstract  210-0)

  33. Herold KC, for the Type 1 Diabetes TrialNet Study Group, the TrialNet Study Group Mechanistic Assay Committee, and the TrialNet T-Cell Assay Group.  Report of the TrialNet T-Cell Validation Study in Type 1 Diabetes.  Diabetes 2007; 56:(Supplement 1): A-319 (Abstract  1299-P)

  34. Mari A, Ferrannini E, Skyler JS, and the DPT-1 Study Group.  Mechanisms of Progression to Diabetes in Relatives of Type 1 Diabetic Patients.   Diabetes 2007; 56:(Supplement 1): A-384 (Abstract  1499-P)

  35. Sosenko JM, Wherrett D, Rafkin-Mervis L, Palmer JP, Skyler JS, and the DPT-1 Study Group.   Metabolic Characteristics of Converters to ICA Positivity in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2007; 56: (Supplement 1): A-482 (Abstract  1907-P)

  36. Mahon J, Sosenko J, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth G, Palmer J, Thompson C, Skyler J,for the Type 1 Diabetes TrialNet Study Group.  The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study.  Diabetes 2007; 56:(Supplement 1): A-486 (Abstract  1922-P)

  37. Chase HP, Asare S, Greenbaum C, Lachin J, Lescheck E, Krause-Steinrauf H, Rafkin-Mervis L, Clare-Salzler M, for the Type 1 Diabetes TrialNet NIP Study Group.  Nutritional Intervention to Prevent (NIP) Type 1 Diabetes.  Diabetes 2007; 56:(Supplement 1): A-689 (Abstract  2723-PO)

  38. Krischer JP for the Type 1 Diabetes TrialNet Oral Insulin Study Group.  Oral Insulin For the Prevention Of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus (T1DM).  Diabetes 2007; 56:(Supplement 1):  A-699 (Abstract  2764-PO)

  39. Mahon J, Sosenko JM, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth GS, Palmer JP, Thompson C, and The Type 1 Diabetes TrialNet Study Group.  The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study.  Acta Diabetologia 2007; 44:(Supplement 1): S 30.

  40. Herold K for the Mechanistic Outcomes Committee and the Type 1 Diabetes TrialNet Study Group.  Report from TrialNet: Diagnostic Accuracy and Reproducibility of T-Cell Responses to Islet Antigens in Subjects with Recently Diagnosed Type 1 Diabetes.  Acta Diabetologia 2007; 44:(Supplement 1): S 21.

  41. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Skyler JS, and the DPT-1 and Type 1 Diabetes TrialNet Study Groups.  Comparison Between Participants of the TrialNet Natural History Study and Participants of the Diabetes prevention Trial-Type 1.  Acta Diabetologia 2007; 44:(Supplement 1): S 50.

  42. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group.   Glucose and C-Peptide Changes in the Peri-onset Period of Type 1 Diabetes in the Diabetes Prevention Trial – Type 1 (DPT-1).   Acta Diabetologia 2007; 44:(Supplement 1): S 49-50.

  43. Ferrannini E, Nofrate V, Skyler JS, Mari A, for the DPT-1 Study Group.   Progression to diabetes in relatives of people with type 1 diabetes: predictors and mode of onset.  Diabetes 2008; 57:(Supplement 1): A-45 (Abstract 150-OR).

  44. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups.  Comparisons of OGTT Indices between Participants of the TrialNet Natural History Study and Participants of the Diabetes Prevention Trial-Type 1.  Diabetes 2008; 57:(Supplement 1): A-264 (Abstract 914-P).

  45. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group.   The Loss of Post-Challenge C-Peptide Levels in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2008; 57:(Supplement 1): A-502 (Abstract 1810).

  46. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group.   Incident Post-Challenge Dysglycemia as a Predictor of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2008; 57:(Supplement 1): A-66 (Abstract 228-OR).

  47. Triolo TM, Chase HP, Barker JM, and the DPT-1 Study Group.  Subjects Diagnosed with Diabetes through the Diabetes Prevention Trial Type 1 (DPT-1) are Often Asymptomatic and Have Rare Ketosis at Onset.  Diabetes 2008; 57:(Supplement 1): A-501-502 (Abstract 1807).

  48. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group.The Timing of the Peak C-Peptide and Its Prediction of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2009; 58: (Supplement 1): Abstract 22-OR.

  49. Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, Mcgee P, Krause-Steinrauf H, for the Type 1 Diabetes Trial Network (TrialNet).  In Vivo Immune Responses in Type 1 Diabetes Following Treatment with Rituximab. Diabetes 2009; 58: (Supplement 1): Abstract 195-OR.  

  50. Jeffrey J, Eisenbarth GS, Fain PR, Yu L, Miao D.  Persistent but Not Transient Biochemical Islet Autoantibody Expression Is Increased in Prospectively Followed Monozygotic Versus Dizygotic Twins.Diabetes 2009; 58: (Supplement 1): Abstract 1141-P.

  51. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group.Trends of Earlier and Later C-Peptide Responses to Oral Glucose with Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).  Diabetes 2009; 58: (Supplement 1): Abstract 1801-P.

  52. Vehik K, Haller MJ, Xu P, Schatz DA, Krischer J, DPT-1 Study Group.  Seroconversion in the DPT-1 Study: evidence of triggering of autoimmune process at different ages.  Diabetologia 2009; 52:(Supplement 1)S 119 (Abstract 277).

back to top of page